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Background: Cancer cell metabolism can be characterised by adaptive metabolic alterations, which support abnormal proliferative cell growth
with high energetic demand. De novo nucleotide biosynthesis is essential for providing nucleotides for RNA and DNA synthesis, and drugs
targeting this biosynthetic pathway have proven to be effective anticancer therapeutics. Nevertheless, cancers are often able to circumvent
chemotherapeutic interventions and become therapy resistant. Our understanding of the changing metabolic profile of the cancer cell and the
mode of action of therapeutics is dependent on technological advances in biochemical analysis.
Scope of review: This review begins with information about carbon- and nitrogen-donating pathways to build purine and pyrimidine moieties in
the course of nucleotide biosynthesis. We discuss the application of stable isotope resolved metabolomics to investigate the dynamics of cancer
cell metabolism and outline the benefits of high-resolution accurate mass spectrometry, which enables multiple tracer studies.
Conclusion: With the technological advances in mass spectrometry that allow for the analysis of the metabolome in high resolution, the
application of stable isotope resolved metabolomics has become an important technique in the investigation of biological processes. The literature
in the area of isotope labelling is dominated by 13C tracer studies. Metabolic pathways have to be considered as complex interconnected networks
and should be investigated as such. Moving forward to simultaneous tracing of different stable isotopes will help elucidate the interplay between
carbon and nitrogen flow and the dynamics of de novo nucleotide biosynthesis within the cell.
 2019 Max Delbruck Center for Molecular Medicine in the Helmholtz Association. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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BIOSYNTHESIS
Cancer cells reprogram their metabolism to enable cell growth,
biomass synthesis, and proliferation due to the induction of oncogenes
or the loss of tumour suppressors. Otto Warburg conducted one of the
first quantitative metabolic studies in the 1920s [1]. Warburg observed
that tumours consume excessive amounts of glucose and ferment the
majority to lactic acid even in the presence of oxygen. Warburg
assumed that the shift from mitochondrial respiration to aerobic
glycolysis in cancer cells may be caused by impaired mitochondria [2].
Indeed, this was disproved by Weinhouse through one of the early
examples of isotopic labelling in respect to tumour metabolism.
Weinhouse observed that the quantity of labelled CO2 produced by
oxidative phosphorylation, performed by functioning mitochondria,
occurs at the same rate in cancer cells as in normal cells [3]. Through
decades of research on the “Warburg Effect,” it has become clear that
the enhanced rerouting of glucose into lactic acid is accompanied by a
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hallmark of a cancer cell with respect to the Warburg Effect is an
increased glucose uptake to fuel adenosine triphosphate (ATP) pro-
duction via lactate. The preference for the production of ATP via lactate
rather than oxidative phosphorylation seems counterintuitive; 2 mol of
ATP are generated per mole of glucose via lactate, whereas oxidative
phosphorylation provides 36 mol of ATP. The advantages that this
metabolic alteration confers have been highly disputed.
Metabolic alterations in the cancer cell are not limited to increased
glucose metabolism. To accommodate the demand of nitrogen and
carbon for nucleotide synthesis, cancer cells enhance the consumption
of both glucose and glutamine. While glucose is one of the most
important carbon sources, glutamine provides both carbon and nitro-
gen. Usually, metabolic networks are constructed from the carbon flow
perspective through 13C isotope labelling experiments. The inclusion of
further isotope labels (e.g., 15N nitrogen) promises to obtain a more
comprehensive metabolic picture (Figure 1). Simultaneous labelling
experiments may provide new insights into the interaction of metabolic
pathways. A better understanding of alterations in cancer cellfor Medical Systems Biology (BIMSB), Berlin, Germany 3German Cancer Research
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metabolism could facilitate the development of novel therapeutics and
may aid treatment strategies, especially to prevent drug resistance. To
analyse the entire interactive and dynamic network of a cancer cell, an
approach providing an overall systemic perspective is required.
Traditional linear thinking has been proven to be too limited to un-
derstand the multifaceted network of these molecular interactions [5].
In this framework, systems biological studies are needed to improve
our understanding of the biological and physiological complexity of the
disease. Mathematical and computational techniques are indispens-
able to process comprehensive data sets, obtained by high-throughput
methods in proteomics, metabolomics, and genomics [6,7]. The basic
knowledge on metabolic pathways often fails to explain therapeutic
resistances, because metabolic reprogramming is difficult to predict,
and the metabolic crosstalk between several cell types within a tumour
enhances the metabolic repertoire of cancer.
1.1. Glycolysis
An enhanced glucose uptake and metabolism fuels cancer cells with
the necessary ATP and carbons for growth and proliferation. The
measurement of this dynamic system is paramount in understanding
the metabolic differences between cell types and their pathologies. The
metabolism of glucose branches into multiple pathways and requires
the analysis of the flux of carbon through central carbon metabolism:
glycolysis, pentose phosphate pathway (PPP), TCA cycle, and amino
acid metabolism. Because of the rapidity of the flow of carbon throughNH3
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Figure 1: Glutamine-centric nitrogen metabolism with focus on amino acids and
nucleotides. Abbreviations: inosine-monophosphate (IMP), guanosine-monophosphate
(GMP), adenosine monophosphate (AMP), cytidin triphosphate (CTP), uridine mono-
phosphate (UMP), glutamine (gln), asparagine (asn), aspartate (asp), glutamate (glu),
serine (ser), glycine (gly), alanine (ala), formyl-glycine-amide-ribonucleotide (FGAR),
formyl-glycine-amidine-ribonucleotide (FGAM), 5amino-imidazol-4-N-succino-carbox-
amid-ribonucleotide (SAICAR).
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In many cancer cells, enzymatic elements of these pathways are
overexpressed to compensate for their metabolic demands. As an
example, in the last step of glycolysis, pyruvate kinase (PKM) converts
phosphoenol pyruvate into pyruvate. Cancer cells commonly increase
the expression of the PKM splice variant PKM2. The lower activity of
PKM2 contributes to an accumulation of upstream glycolytic in-
termediates, leading to an increased flux into adjacent pathways, for
example, the PPP and the one-carbon metabolism [9]. Through iso-
topic tracing, it has been observed that the PKM2 variant supports the
synthesis of nucleotides, and the deletion of PKM2 causes a nucleotide
crisis via thymidine [10].
The PPP branches at two distinct points in the preparatory phase of
glycolysis, using different intermediates for the production of ribose-5-
phosphate (R5P). The oxidative pathway branches from glucose-6-
phosphate (G6P), and the nonoxidative pathway branches from fruc-
tose-6-phosphate (F6P), combining with glyceraldehyde-3-phosphate
(G3P) to cycle carbons to R5P (Figure 2). Both these pathways have
been found to be elevated in cancers, to support NADH and nucleotide
intermediates synthesis [11]. However, through [1,2e13C] glucose
tracing, it has been observed that the non-oxidative pathway takes
precedence in, at least, leukaemic and colon cancer cells [12,13].
Clearly, there is a wealth of research addressing the carbon flow
through the PPP to R5P from glucose. Yet, there is scope to describe
the role of nitrogen sources for nucleotide synthesis, particularly in the
context of the mode of action of therapeutics.
Cancer cells with elevated PKM2 harbour increased 3-phosphoglyceric
acid (3-PGA). 3-PGA is an intermediate of glycolysis and fuels serine
and glycine production. Serine is synthesised by three steps emerging
from 3-PGA. As a subsequent step, glycine is synthesised via the
enzyme serine hydroxymethyltransferase (SHMT). Serine and glycine
provide precursors for nucleic acids via refuelling the one-carbon
metabolism (Figure 2). The conversion of serine to glycine via SHMT
is part of the one-carbon metabolism, which turns into the folate cycle.
Simultaneously to glycine production, the enzyme SHMT converts
tetrahydrofolate (THF) to 5,10-methylene-THF (5-formyl-THF). Subse-
quently, 5-formyl-THF is converted to 10-formyltetrahydrofolate
(F-THF) (Figure 2). In addition, glycine is incorporated into
5-phosphoribosyl-1-amine to produce formyl-glycine-amide-
ribonucleotide an early intermediate in purine biosynthesis. In sum-
mary, glycine and the folate cycle together provide one nitrogen and
two carbon atoms for the building of the purine ring.
Recent research addressing the role of phosphoglycerate dehydroge-
nase, which catalyses the first step of 3-PGA to serine metabolism,
showed that its inhibition results in a depletion of nucleotides.
Furthermore, by tracing both the carbon and nitrogen flow, it was
found that serine, not glycine, is essential for cancer cell proliferation
[14,15]. Functional tracing of carbon and nitrogen flow through the
cancer metabolic profile requires the understanding of the roles of
glutamine and asparagine, in combination with glucose studies.
1.2. Glutamine and asparagine metabolism
In addition to glucose, glutamine is a major nutrient used by cancer
cells [16]. Glutamine fuels anaplerotic reactions to maintain the TCA
cycle function and mitochondrial integrity. It is known that the depletion
of glutamine causes cell death [16]. This phenomenon, termed
glutamine addiction, has been observed in a variety of cancer types
in vitro and in vivo [17]. Glutamine provides the carbon skeleton for the
TCA cycle and contributes to protein synthesis (Figure 2). Glutamine is
essential as a nitrogen donor within de novo nucleotide biosynthesis,sociation. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http:// 39
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Figure 2: Pathways carrying the nucelotide biosynthesis. The ribonucleotides show carbon and nitrogen derived from independent pathways illustrated by the corresponding
colours.
Reviewfor both purines and pyrimidines. In addition, it donates nitrogen via
aminotransferases to produce, amongst others, aspartate. Oxaloace-
tate- and glutamine-derived glutamate is converted via the enzyme
aspartate transaminase to alpha-ketoglutarate and aspartate
(Figure 2). The latter is an important nitrogen donor to purine and
pyrimidine synthesis. This metabolic dependency has been extensively
studied to elucidate novel therapeutic approaches that are based on
the concept of glutamine addiction. The present knowledge seems not
to be sufficient to identify novel targets and to explain therapeutic
resistances. Investigating the flow of glutamine’s nitrogen, in addition
to glucose’s carbon, could help to gain further insight in this regard.
Several cancer cells have the ability to produce glutamine via gluta-
mine synthase (GS). It has been found that high GS-expressing glio-
blastoma cells were less sensitive to glutamine deprivation compared
with low-GS-expressing cells [18]. High GS expression led to more
stable purine levels under glutamine starvation, while pyrimidine levels
were barely affected in the studied cell types. 15N-ammonia labelling
revealed a direct incorporation of ammonia into nucleotides. While
glutamine and aspartate are involved in both purine and pyrimidine
synthesis, glycine contributes only to purine synthesis. This raises the
question as to whether the impact of glutamine deprivation on glycine
synthesis impedes the formation of purines. Furthermore, the sup-
pression of glutamine synthesis in high-glutamine synthetase-
expressing cancer types may improve the outcome of chemo-
therapy. This requires a detailed understanding of how glutamine
production is facilitated within the cells described, in particular the
origin of glutamines amido group. To investigate the role of nitrogen40 MOLECULAR METABOLISM 33 (2020) 38e47  2019 Max Delbruck Center for Molecular Medicine in the Hdonors in de novo purine synthesis, labelling with 15N-glutamine will
allow tracing of nitrogen into purine intermediates and elucidate
mechanisms of regulation [19].
Zhang et al. identified asparagine-producing pathways in glioblastoma
to be advantageous for survival under glutamine starvation [20]. The
enzyme citrate synthase catalyses the condensation of acetyl-CoA and
oxaloacetate to citrate in the first step of the TCA cycle. Silencing of this
enzyme induced the production of aspartate and asparagine from
oxaloacetate and rescued for glutamine deprivation. The role of the
aspartate nitrogen has to be clarified in this context. Aspartate sup-
ports the formation of glutamate, the precursor for glutamine syn-
thesis, on the one hand, and the formation of purine and pyrimidine
rings for nucleotide synthesis on the other hand. The enzyme pyruvate
dehydroxygenase is involved in the formation of acetyl-CoA from py-
ruvate, and its inhibition prevents apoptosis under glutamine starva-
tion. Asparagine deprivation sensitised cells to glutamine withdrawal,
while asparagine addition prevented apoptosis. This leads to the hy-
pothesis that the ability to redirect oxaloacetate consumption to
aspartate and asparagine production could circumvent the detrimental
effects of glutamine deprivation. This assumption was confirmed by
Cheng et al., who identified pyruvate carboxylase (PC) activity to be
compensating for glutaminase silencing [21]. PC provides another
pathway for pyruvate to enter the TCA cycle. This step forms oxalo-
acetate, the precursor for aspartate and asparagine. Pavlova et al.
further investigated the role of asparagine in cancer metabolism [22].
They observed an increased GS expression after asparagine addition
only when it was not catabolised to aspartate. Krall et al. alsoelmholtz Association. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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emphasised that the beneficial role of asparagine cannot be explained
by catabolism and is more likely to be a result of its ability to facilitate
amino acid uptake [23]. Interestingly, a 15N2-asparagine isotope
tracing experiment resulted in approximately 10% nitrogen incorpo-
ration into purines, while no other incorporation events have been
observed. Asparagine nitrogen is not directly involved in purine
biosynthesis, and the amino acids that normally contribute their ni-
trogen to purine synthesis remained unlabelled [23]. This raises the
question regarding which mechanisms introduced the observed labels.
Dynamic isotope labelling strategies that enable the analysis of in-
stationary isotope incorporation will be beneficial to investigate such
phenomena.
1.3. Fuelling purine and pyrimidine biosynthesis
Glycolysis, PPP, glutaminolysis, and amino acid metabolism are con-
nected and converge to provide precursors for nucleotide biosynthesis.
The amino acids glutamine, glycine, and asparagine play an important
role as nitrogen donors in inosine-monophosphate (IMP) biosynthesis.
IMP is the precursor for purine nucleotides: adenosine monophosphate
(AMP) and guanosine monophosphate (GMP). IMP synthesis requires
two amide nitrogen from glutamine, one amino nitrogen from glycine,
and one further amino nitrogen from aspartate. The conversion to AMP
uses a further aspartate nitrogen, while glutamine provides an addi-
tional nitrogen to GMP production (Figure 3). The synthesis of pyrim-
idine nucleotides involves up to three amino acidedependent steps.
First, glutamine donates its nitrogen in a rate-limiting step to the
formation of carbamoylphosphate (CBMP). CBMP subsequently con-
denses with aspartate, and further reactions provide uridine mono-
phosphate (UMP). UMP-derived uridine triphosphate (UTP) can be
converted to cytidin triphosphate (CTP) in a glutamine-dependent re-
action (Figure 4). In a concerted manner, these central metabolic
pathways fuel de novo nucleotide biosynthesis. A quantitative and
time-resolved analysis of these metabolic branching points may pro-
vide new insights into metabolic reprogramming and drug resistance.
2. TARGETING NUCLEOTIDE BIOSYNTHESIS FOR CANCER
THERAPY
Dividing cells require nucleotides to synthesise RNA and DNA. Central
metabolic pathways such as glycolysis, one-carbon metabolism,
glutamine, and amino acid metabolism contribute carbon and nitrogen
atoms in a concerted manner to fuel de novo nucleotide biosynthesis.
2.1. Targeting de novo nucleotide biosynthesis
A number of chemotherapeutics are antimetabolites that target de novo
nucleotide biosynthesis. They either mimic a metabolite and inhibit thePPRP
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Figure 3: Amino acidedependent steps of purine nucleotide biosynthesis. Nitrogens are d
which they were derived. Abbreviations: 5-phosphoribosyl-1-pyrophosphate (PRPP), 5-phos
amidine-ribonucleotide (FGAM), 5amino-imidazol-4-N-succino-carboxamid-ribonucleotide
monophosphate (GMP), glutamine (gln), glycine (gly), aspartate (asp), glutamine-PRPP-a
synthase (SAICARS), adenylosuccinate synthetase (ADSS), GMP-synthase (GMPS).
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and subsequently stop the respective pathway. Transformed cells opti-
mise nucleotide biosynthesis for rapid cell proliferation. To disturb this
process, the well-investigated compound 5-fluoruracil (5-FU) is used for
the treatment of different cancer types. By mimicking uracil, 5-FU inhibits
the enzyme thymidylate synthase (TYMS), which methylates deoxyuridin
phosphate to deoxythymidin phosphate using me-THF [24]. Thus, 5-FU
blocks DNA synthesis and subsequently cell division; however, the effi-
cacy of 5-FU in the clinics is limited. This is surprising, as no other re-
actions are known to contribute to thymidine-nucleotide biosynthesis. The
inhibition of 5-formyleTHF synthesis, an important cofactor of TYMS,
seems to be more effective. For example, the drug methotrexate (which
inhibits dihydrofolate reductase [DHFR]), and the antimetabolite peme-
trexed (which inhibits TYMS, DHFR, and glycinamide ribonucleotide for-
myltransferase [GARFT]) target the synthesis of folate cofactors and
thymidinenucleotides [25,26]. These drugs are mostly used in combi-
nation with cis-platin [27]. Cisplatin can affect DNA replication and in-
duces DNA damage. Another DNA synthesis inhibitor is hydroxyurea (HU),
which targets ribonucleotide reductase (RNR), first established in 1963 as
new antitumor agent by Stearns et al. [28]. RNR is the only enzyme
converting ribonucleotides to deoxyribonucleotides and presents a
promising target; as a result, it has been the focus of many studies. RNR
provides dNTP pools for DNA replication and repair [29]. However, the
application of HU as a therapeutic induces severe side effects in patients.
Although nucleotide biosynthesis is an essential metabolic process,
therapeutic targeting of this metabolic network did not yield the final re-
sults that a biochemist would predict. A subsection of tumours are re-
fractory after initial therapy, and relapsing tumours can establish a
resistance against drugs targeting de novo nucleotide biosynthesis.
In addition to antimetabolites and drugs that target nucleotide
biosynthesis directly, the precursor phase of nucleotide biosynthesis
can be targeted with small molecules. Carbon and nitrogen atoms for
nucleotide biosynthesis are provided by central metabolic pathways
and converge in a multistep process to from purine and pyrimidine
nucleotides. Thus, targeting central metabolic pathways also affects
nucleotide synthesis. However, the plasticity of the central metabolic
network can often circumvent blockages induced by drug treatments.
2.2. Targeting glutamine metabolism
Glutamine is a nonessential amino acid and is required for de novo
nucleotide biosynthesis. Several enzymes that directly participate in
nucleotide synthesis use glutamine as nitrogen donor. The enzyme
glutaminase was found induced in cancer [30,31] and was anticipated
as an effective metabolic target. Glutaminase is a deaminating enzyme
that converts glutamine to glutamate. Glutamate is further metabolised
to alpha-ketoglutarate and channelled into the TCA cycle. However,SAICAR IMP
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Figure 4: Amino acidedependent steps of pyrimidine nucleotide biosynthesis. Nitrogens are depicted as circles. Colours of nitrogen correspond to the colours of the amino acids
from which they were derived. Abbreviations: carbamoylphosphate (CBMP), uridine monophosphate (UMP), uridine triphosphate (UTP), cytidin-triphosphate (CTP), carbamoyl-
phosphate synthetase-2 (CPS2), aspartate transcarbamylase (ATCase), CTP-synthase-1 (CTPS1), glutamine (gln), aspartate (asp).
Reviewtargeting glutaminase using small-molecule inhibitors was not effec-
tive to significantly reduce carbon flow into the TCA cycle [32]. It may
be postulated that additional reactions that convert glutamine to
glutamate could bypass glutaminase inhibition. Furthermore, Leone
et al. stated that the therapeutic response in vivo to targeted blockade
of glutaminase is limited [33]. In this study, the authors focused on 6-
diazo5-oxo-L-norleucine (DON). DON is a bacterial compound and
structural analogue of glutamine that is expected to inhibit a wide
range of glutamine-metabolising enzymes. In vitro application of DON
led to a reduced glutamine-derived 15N incorporation in formyl glyci-
namide ribonucleotide (FGAR); an early intermediate of purine
biosynthesis (Figure 3). The authors could also show that the effect of
DON on protein level of the MYC oncogene [32] exceeds the shRNA
knock down of single nucleotide biosynthetic enzymes by far. How-
ever, the target(s) of DON remained elusive. To better understand the
dynamics of this network and the stoichiometric contribution of ni-
trogen and carbon providing pathways at their points of convergence, a
dynamic analysis of carbon and nitrogen flow will be indeed beneficial.
The method pulsed stable isotope resolved metabolomics (pSIRM), an
approach to create time series of isotope incorporation before the
isotopic steady state has been reached [8], may be the foundation for
further developments that allow the analysis of multiple tracers at the
same time. pSIRM may also enable the support of the identification of
drug actions (e.g., DON) at complex metabolic networks.
3. ANALYSIS OF CENTRAL METABOLIC NETWORKS USING
STABLE ISOTOPE RESOLVED METABOLOMICS
Central carbon metabolism and nucleotide biosynthesis are complex
metabolic pathways. A single measurement “snapshot” can offer only a
static picture of an actually dynamic system. The principles that lead to the
metabolic homeostasis remain rather elusive. For example, an increased
concentration of a certain metabolite may be caused by accelerated
production, reduced degradation, or both. To understand these underlying
mechanisms, it is important to decipher the cellular response to pertur-
bations (e.g., drug treatments). To resolve such dynamics of intracellular
metabolic pathways, isotope labelling can be applied. Different technol-
ogies enable an isotope-assisted analysis of such networks. Nuclear
magnetic resonance (NMR) spectroscopy is a nondestructive approach
that allows for absolute quantification and in vivo analysis [34,35].
However, mass spectrometry (MS) is currently favoured because of its
higher sensitivity and lower cost. NMR spectroscopy allows for the
analysis of positional isotope enrichment. In contrast, MSdoes not provide
positional information without additional efforts (e.g., fragmentation).
Each peak in a mass spectrum is related to a set of isotopologues that can
differ in their positional composition of isotopes. Fragmentation of mol-
ecules, induced through electron impact ionisation, allows for the iden-
tification of positional isotope enrichment [36].
3.1. Isotope labelling experiments
Isotope labelling experiments are suitable to observe relative pathway
contributions as well as the metabolic fate of small molecules within a
cell. The concept is based on the fact that molecules of the same42 MOLECULAR METABOLISM 33 (2020) 38e47  2019 Max Delbruck Center for Molecular Medicine in the Hspecies differ naturally in their molecular mass. Molecules that differ in
their isotope composition are termed isotopologues. Isotopologues that
carry the same number of isotopes but on different positions are
defined as positional isotopologues or isotopomers. Thus, nonposi-
tional isotopologues can be easily distinguished by their masses, while
separation of isotopomers requires at least the application of a MS
technique that allows for fragmentation.
13C labelling experiments are a frequent choice to investigate meta-
bolism [37,38]. The naturally high abundant carbon isotope is 12C, and
the heavier stable 13C accounts for approximately 1.1%. Thus, under
normal conditions, the vast majority of carbon compounds will be
measurable as 12C isotopologues. The consumption of isotopic labelled
substrates induces 13C enrichment in downstream intermediates. The
enrichment can be observed by MS analysis as a mass shift (i.e., an
increase in the intensities of heavier isotopologue peaks). Comparing
such observations under different conditions gives a first impression
on how nutrient availability or drug treatment affects metabolic pro-
cesses. Single metabolites can be produced by multiple redundant
pathways. Such pathways can differ in how they use carbons to form a
certain metabolite. Figure 5 shows different ways to form citrate or
oxaloacetate and how labelling patterns differ, depending on the
carbon flow, when tracing with 13C-u glucose or 13C-u glutamine. The
appropriate choice of number and position of isotopic labelled carbons
within a substrate may elucidate the activity of different pathways by
producing distinct isotope patterns. In this regard, the choice of tracer
can depend on the pathway of interest [39,40]. Jang et al. outlined how
to interpret the results of several pathway-specific labelling experi-
ments [41].
3.2. Flux analysis
The determination of the metabolic flux promises a more compre-
hensive understanding of the dynamics within a metabolic network.
Metabolic fluxes describe the turnover of chemical reactions in terms
of reaction rates. Extracellular fluxes can be measured by secretion
and consumption, yet the determination of intracellular fluxes is not as
trivial. Simple balanced networks can be described by linear equations,
given their stoichiometry, and fluxes can be calculated by flux balance
analysis [42]. This approach fails for more complex systems that
exhibit cycles, reversible reactions, or parallel fluxes. Measurements
from labelling experiments are used to simulate fluxes for those net-
works by metabolic flux analysis (MFA). Simulations are based on the
assumption that the investigated organism meets the metabolic
steady-state condition, in which fluxes and metabolite concentrations
are constant. Fluxes are determined by an optimisation method that fits
initially estimated values to the measured data [43]. Once a set
of fluxes has been determined, confidence intervals describe the
probability that a variant set of fluxes would produce similar mea-
surements [44].
3.3. Metabolic and isotopic steady state and in-stationary MFA
Most isotope labelling approaches assume the system fulfils the
metabolic steady-state condition. In this state, metabolite concentra-
tions do not change over time. While overall metabolite concentrationselmholtz Association. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 5: 13C-u glucose or glutamine routing. The flux of 13C-u glucoseederived pyruvate through PDH results in mþ2 citrate, the flux through PC results in mþ3 citrate, and the
combination of both results in mþ5 citrate. 13C-u glutamine tracing leads to mþ4 or mþ5 citrate. Solid circles depict 13C carbons; empty circles depict 12C carbons. Abbreviations:
glucose (glc), pyruvate (pyr), acetyl-CoA (AcCoA), cytidin triphosphate (CTP), oxaloacetate (oaa), a-ketoglutarate (aKG), glutamine (gln), pyruvate carboxylase (PC), pyruvate
dehydroxygenase (PDH). Adapted from [59].are assumed to be constant in the metabolic steady state, the intro-
duction of isotopic labelled substrates to the system results in a dy-
namic enrichment of isotopes. This is a finite process, and at some
point, metabolite pools are constantly enriched with isotopes. This is
the onset of the isotopic steady state. Nondynamic tracing studies
choose labelling times to reach the isotopic steady state. The duration
until this state is reached depends on the pathways under consider-
ation and the experimental setups. Glycolysis, for example, can
equilibrate within 10 min after glucose labelling, while TCA cycle in-
termediates are normally not balanced before 2 h. Labelling times for
nucleotides should be at least 24 h [41]. More reliable results may be
obtained by in-stationary MFA [45e47]. However, the experimental
requirements are high with regard to measured time points and rep-
etitions. While classical metabolic flux analyses are based on mea-
surements taken at the isotopic steady state, the in-stationary MFA is
based on multiple measurements taken before the isotopic steady
state has been reached. Such time series may better represent the
dynamics of the metabolic system. The experimental design needs to
be adapted to perform multiple measurements before the system
enters the isotopic steady state. This increases the effort of sample
collection and preparation as well as computational demands. For
mathematical modelling, the metabolic steady state is still assumed.
Multiple measurements of the metabolic profile in the presence of a
drug, through time, presents uncertainties on designing the correct
experimental conditions. The primary metabolic response to drug
treatment is dependent on the target itself and the metabolic activity of
the cell. After the initial metabolic disturbance, the system will adapt at
all regulatory layers, and it cannot be ensured that metabolism fulfils
the steady state condition at the time point of measurement, or if the
obtained results just reflect the metabolic target.
3.4. Pulsed stable isotope resolved metabolomics for analysis of
pathway activity and drug response
Stable isotope-assisted methods such as pSIRM [8] or kinetic flux
profiling [48] apply stable isotope labelled substrates for short time
periods and analyse isotope incorporation into metabolism, even if the
isotopic steady state is not reached. The information of isotope
enrichment and quantity of a certain metabolite together allow a real
estimate of isotope incorporation over time. Specifically, if the action of
a metabolic inhibitor should be analysed, such analysis is informative.
The action of metabolic inhibitors may target the biochemical networkMOLECULAR METABOLISM 33 (2020) 38e47  2019 Max Delbruck Center for Molecular Medicine in the Helmholtz As
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mately, this leads to adaptations of cellular signalling and subsequently
transcription and translation. To resolve time-dependent processes, it
is necessary to obtain dynamic metabolic measurements at early,
intermediate, and late time points. For example, Pietzke and Zasada et
al. analysed the action of 2-deoxyglucose (2-DG), an often used
metabolic inhibitor, within 15 min [49]. Using the pSIRM technology
after a short application of 2-DG revealed that 2-DG is converted by
hexokinase to 2-DG phosphate. 2-DG phosphate is produced at a
millimolar concentration and thereby sequesters the cellular ATP pool.
However, 2-DG is not an inhibitor of hexokinase per se, as usually
stated in the literature. In addition, an activation of citrate production,
probably through activation of AMPK and pyruvate dehydrogenase,
could be observed. Thus, the combination of short time label incor-
poration and measurement of absolute metabolite concentrations allow
quantitative and dynamic insights into metabolism and to uncover
actions of drugs or oncogenes [8,50].
3.5. Towards multiple tracer studies
Current tracer applications are based on 13C studies to investigate the
central carbon metabolism and its branching pathways. The imple-
mentation of further stable isotopes such as 2H, 18O, 34S, or 15N
predominantly allows for additional insights into the metabolic
behaviour of cells. To understand the role of glucose and glutamine as
both carbon and nitrogen donors, it may be beneficial to simulta-
neously trace 13C and 15N. Common MS techniques are coupled to
separation methods such as gas chromatography (GC) or liquid
chromatography (LC). GC is most often used in combination with low-
or medium-resolution mass analysers such as time of flight (ToF) or
quadrupole. However, it is not possible to distinguish carbon- and
nitrogen-induced mass shifts using GCeMS technologies, which
produce only nominal mass spectra (Figure 6). The same issue
emerges using instruments with high mass accuracy but only low or
medium resolution. LC-MS Orbitrap systems or high-resolution multi-
reflectron ToFs can provide enough accuracy, resolution, and scan
speed to distinguish isotopologues that contribute to the same isotopic
peak in nominal spectra (Figure 7). For some years, commercial GC
instruments have been available that also enable the analysis of
simultaneous tracer studies [51,52].
An important step in the evaluation of labelling experiments is the
correction for natural isotope abundances. To determine thesociation. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http:// 43
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Figure 6: Comparison of carbon and nitrogen induced mass shifts in either nominal spectra (integer mass values) or exact spectra (masses with a precision of about 5 decimal
places). A) The simulated nominal spectrum of a glutamine fragment with a 50% incorporation of one carbon. B) The simulated nominal spectrum of a glutamine fragment with a
50% incorporation of one nitrogen. There is no difference from A). C) The m/z ¼ 157 peak of A) resolved to exact masses. The 13C peak is dominant and shows that the mass shift
in A) was mainly induced by the 13C incorporation. D) The m/z ¼ 157 peak of B) resolved to exact masses. The 15N peak is dominant and shows that the mass shift in B) was
mainly induced by 15N incorporation.
Reviewexperimental isotope enrichment, data points first have to be adjusted
according to the natural abundances of the used tracer. Several ap-
proaches to accomplish data correction have already been published
[53,54]. These approaches predominantly focus on data containing
nominal spectra, derived from single-tracer experiments, and mostly
using reference measurements. Carreer et al. presented a computa-
tional framework to correct highly resolved accurate mass spectra,
derived from multiple tracers for natural abundances [55]. The
correction of an 13C, 15N enriched analyte/fragment spectrum requires
the following steps:
1. Identify in each isotope peak the number of heavy carbons and
nitrogens.
2. Generate a data set D ¼ (Ik,l), so that Ik,l equals the sum of all in-
tensities of peaks that contain exactly k 13C and l 15N atoms.
3. Correct the data set D to obtain a data set D’ ¼ (I’k,l)). After the
correction, the values I’k,l correspond to the actual experimental
enrichment of isotopologues that carry exactly k 13C and l 15N
atoms.
The correction is based on the following principles: A certain amount of
Ik,l corresponds to isotopologues with an experimental
13C and 15NIn
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m
A B
Figure 7: Mass spectra of identical samples under different resolutions: A) 15,000, B) 30,0
15N, and 29Si isotopologues.
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incorporation sums up to k and l only by natural abundance. This
amount has to be subtracted from Ik,l. There may also exist a certain
amount of isotopologues that exhibit an experimental incorporation of k
and l 13C and 15N isotopes plus some additional heavy carbons and
nitrogens by natural abundance. This amount is not tracked by Ik,l and
has to be added (Figure 8). For completeness, it has to be mentioned
that derivatisation methods for GC introduce additional atoms to the
molecule, for example, through trimethylsilyl or tert-butyldimethylsilyl
groups. As silicon has two high abundant isotopes, this has to be
considered within the natural abundance correction when only nominal
spectra are available. Regarding the correction of high-resolution ac-
curate mass spectra according to the mentioned algorithm, GCeMS
derivates require no additional attention.
4. CONCURRENT TRACING: ELUCIDATING THE CROSSROADS
OF CARBON AND NITROGEN METABOLISM
Nucleotide biosynthesis requires an appropriate supply of carbons
(e.g., glucose) that feed the PPP as well as nitrogen from amino acids
that can be synthesised using glutamine among other sources. The
simultaneous labelling of glucose carbons and glutamine nitrogen will/z
15N 29Si 13C
C D
00, C) 60,000, D) 120,000. Ultra-high resolution allows for a reliable distinction of 13C,
elmholtz Association. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 8: Visualization of the correction for natural abundancies of isotopes. The correction of a 13C, 15N enriched analyte/fragment spectrum requires the following steps: i)
Identify in each isotope peak the number of heavy carbons and nitrogen. ii) Generate a data set D ¼ (Ik,l), so that Ik,l equals the sum of all intensities of peaks that contain exactly k
13C and l 15N atoms. iii) Correct the data set D to obtain a data set D’ ¼ (I’k,l). After the correction, the values I’k,l correspond to the actual experimental enrichment of isotopologues
that carry exactly k 13C and l 15N atoms. The correction is based on the following principles: A certain amount of Ik,l corresponds to isotopologues with an experimental
13C and 15N
incorporation smaller than k and/or l, respectively. The measured incorporation sums to k and l only by natural abundance. This amount has to be subtracted from Ik,l. There may
also exist a certain amount of isotopologues that exhibit an experimental incorporation of k and l 13C and 15N isotopes plus some additional heavy carbon and nitrogen atoms by
natural abundance. This amount is not tracked by Ik,l and has to be added. Notations CNk,l indicate an incorporation of k
13C and l 15N atoms.provide detailed insights into the nucleotide metabolism of cancer
cells. To date, only a few studies focused on the concurrent tracing of
carbon and nitrogen [56e58]. They applied GC/combustion/isotope
ratio (GC-C-IR) or Fourier transform ion cyclotron resonance (FT-ICR)
MS. An appropriate separation and efficient identification could also be
provided by a GC ultra-high-resolution MS. Computational methods
have to be established to process the highly complex data gained from
such labelling experiments. Using this advanced methodology, it is
possible to investigate the dynamics of carbon and nitrogen incorpo-
ration at their convergence within the metabolic network. Such studies
will help to understand the flexibility of the cancer metabolic network
and hopefully will highlight metabolic bottlenecks that can be explored
for novel therapeutic interventions. The structures of metabolic path-
ways were discovered decades ago; today’s challenge is to understand
the regulatory principles that underlie these pathways. Many different
cancers have been studied with regard to their pathway usage and
metabolic phenotype. It became evident that inhibition of cell growth is
not sufficient to finally kill the cancer cells in vitro and in vivo [32].
Besides the metabolic interaction of cancer cells with the tumour
microenvironment, cancer cells can reprogram their metabolism to
circumvent metabolic shortcomings introduced by therapeutic drugs.
However, our understanding of the metabolic flexibility of the cancer
metabolic network is sparse. Cancers may employ a variety of
mechanisms that confer drug resistance, for example, exclusion of the
drug from the cells, metabolising of the drug through cytochrome
oxidases, glutathione conjugation, or induction of alternative signalling
pathways. All these processes are energy demanding and may provoke
detectable metabolic adaptations. Although small-molecule inhibitors
of the de novo nucleotide biosynthesis are among the first chemo-
therapeutics, their clinical efficacy cannot be predicted with certainty.
An improved understanding of the metabolic mode of individual tu-
mours and their capacity to rewire the metabolic network to induce
therapy resistance is necessary. In this regard, the analysis of carbon
and nitrogen metabolism and their convergence in the de novo
nucleotide biosynthesis, and at best simultaneously, will be instru-
mental in future cancer research.MOLECULAR METABOLISM 33 (2020) 38e47  2019 Max Delbruck Center for Molecular Medicine in the Helmholtz As
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ABBREVIATIONS
PRPP phosphoribosy pyrophosphate
gln glutamine
glu glutamate
ala alanine
asp aspartate
asn asparagine
ser serine
gly glycine
aKG ketoglutarate
oaa oxaloacetate
pyr pyruvate
glc glucose
GS glutamine-synthetase
CPS2 carbamoylphosphate synthetase-2
GPAT glutamine-PRPP-amidotransferase
FGAMS FGAM-synthase
GMPS GMP-synthase
CTPS1 CTP-synthase-1
GARS GAR-synthetase
SAICARS SAICAR-synthase
ADSS adenylosuccinate synthetase
ATCase aspartate transcarbamylasesociation. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http:// 45
ReviewPDH pyruvate dehydroxygenase
PC pyruvate carboxylase
PRA 5-phosphoribosyl-1 -amine
FGAR formyl-glycine-amide-ribonucleotide
FGAM formyl-glycine-amidine-ribonucleotide
SAICAR 5-amino-imidazol-4-N-succino-carboxamid-ribonucleotide
IMP inosine monophosphate
UMP uridine monophosphate
GMP guanosine monophosphate
AMP adenosine monophosphate
UTP uridine triphosphate
CTP cytidin triphosphate
CBMP carbamoylphosphate
AcCoA acetyl-CoA
MS mass spectrometry
GC gas chromatography
LC liquid chromatography
FT-ICR Fourier transform ion cyclotron resonance
GC-C-IR gas chromatography/combustion/isotope ratio
MFA metabolic flux analysis
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